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Mutations in neurofibromin (NF1) cause the dominant genetic disorder neurofibromatosis type 1. Neuro-
fibromatosis is characterized by Schwann cell–based tumors and skin hyperpigmentation, resulting from both
haploinsufficiency and loss of heterozygosity. The fact that some pigment cells (melanocytes) arise from
Schwann cell precursors suggests that neurofibromin could be required during the common precursor stage. In
this study, we found a missense mutation in neurofibromin in Dark skin 9 (Dsk9) mutant mice, revealing that Nf1
mutations cause skin hyperpigmentation in mice, as they do in humans. Using tissue-specific knockouts, we
found that haploinsufficiency of neurofibromin in melanocytes via Mitf-cre is insufficient to cause darker skin,
whereas haploinsufficiency in bipotential Schwann cell-melanoblast precursors via Plp1-creER is sufficient.
These findings suggest that there is a narrow developmental window during which Nf1 haploinsufficiency acts
on pigment cells. Using fate mapping, we discovered differences in the colonization of the dermis and
epidermis by melanocytes that arise from Schwann cell precursors, an unexpected complexity of melanocyte
development. As homozygous knockout of Nf1 via Mitf-cre is sufficient to cause darker skin, we conclude that
reduced gene dosage can act by a mechanism different from complete gene loss, even when the end result of
both is very similar.
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INTRODUCTION
Neurofibromatosis type 1 is an autosomal dominant genetic
disorder that affects multiple organs with variable expressivity
(Crowe et al., 1956). Patients with neurofibromatosis develop
neurofibromas, which are tumors composed of spindle-
shaped Schwann cells, mast cells, and perineural cells,
combined with collagen and extracellular matrix. Plexiform
neurofibromas grow along nerves and can interfere with
function and give rise to malignant nerve sheath tumors
(Evans et al., 2002). Abnormalities are also found in the
skeletal, cardiovascular, endocrine, gastrointestinal, and
neurological systems of neurofibromatosis patients (Boyd
et al., 2009).
Neurofibromatosis type 1 has a number of pigmentary
manifestations, including generalized skin hyperpigmenta-
tion (Maertens et al., 2007), Cafe´ au lait macules (CALMs),
and skin-fold freckling (De Schepper et al., 2005). Neuro-
fibromatosis type 1 is caused by inherited or sporadic
mutations in the tumor suppressor gene, NF1, which encodes
neurofibromin (Fountain et al., 1989; Wallace et al., 1990).
Neurofibromin is a positive regulator of rat sarcoma virus
oncogene (RAS) inactivation (Cichowski and Jacks, 2001).
Second-hit mutations in NF1 are found in the Schwann cells
of neurofibromas and the melanocytes of CALMs (Maertens
et al., 2006; De Schepper et al., 2008). It has been recently
shown that, in mice, Schwann cells and some melanocytes
arise from a bipotential precursor expressing Proteolipid
protein 1 (Plp1), a component of the Schwann cell myelin
sheath (Adameyko et al., 2009). Other melanocytes arise
directly from the neural crest and migrate along the
dorsolateral pathway. Melanoblasts, immature melanocytes,
migrate through the dermis before invading the epidermis
and its appendages, the hair follicles (Mayer, 1973; Hirobe,
1984; Kunisada et al., 1996; Yoshida et al., 1996). In this
report, we identify a missense mutation in Nf1 in a mouse
with dominantly inherited dark skin and study the role of
neurofibromin in pigmentation.
RESULTS
Positional cloning of Dsk9
The Dark Skin 9 (Dsk9) mutant was recovered during a
dominant ENU mutagenesis screen performed on a C3HeB/FeJ
& 2013 The Society for Investigative Dermatology www.jidonline.org 49
ORIGINAL ARTICLE
Received 29 February 2012; revised 15 May 2012; accepted 4 June 2012;
published online 19 July 2012
1Department of Medical Genetics, University of British Columbia,
Vancouver, British Columbia, Canada and 2Institute of Experimental
Genetics, Helmholtz Zentrum Mu¨nchen, Neuherberg, Germany
Correspondence: Catherine D. Van Raamsdonk, Department of Medical
Genetics, University of British Columbia, 2350 Health Sciences Mall,
Vancouver, British Columbia, Canada V6T1Z3. E-mail: cvr@mail.ubc.ca
Abbreviations: ACTB, beta-actin; Asn, asparagine; CALMs, cafe au lait
macules; Dct, dopachrome tautomerase; Dsk9, dark skin 9; EYFP, enhanced
yellow fluorescent protein; GRD, GTPase-activating protein-related domain;
KO, knock out; LacZ, beta-galactosidase; Lys, lysine; Mitf, microphthalmia;
Nf1, neurofibromin; Plp1, proteolipid protein 1; Ras, rat sarcoma virus
oncogene; SPRED1, sprouty-related, EVH1 domain containing 1;
SSLP, simple sequence length polymorphism; Tuj1, tubulin, beta 3
class III; Vav1, vav 1 oncogene; X-gal, 5-bromo-4-chloro-3-indolyl-B-D-
galactosidase
genetic background (Hrabe de Angelis et al., 2000).
A mild hyperpigmentation of the glabrous skin (ears, tails,
and footpads) is visible in adult Dsk9/þ animals (Figure
1a–c). Dsk9 darkens both the dermis and the epidermis
(Figure 1d and e). In an outcross–backcross mapping strategy
with C57BL/6J, we used darker skin to link Dsk9 to
polymorphic SSLP markers on chromosome 11 (Fitch et al.,
2003). Subsequently, an outcross–intercross mapping strategy
was used when it was determined that homozygosity of the
dark skin–linked region of chromosome 11 bearing Dsk9 is
homozygous lethal (46 Dsk9/Dsk9 expected, 0 observed).
From these mapping crosses, Dsk9 was localized to a
4.3-Mb physical interval on chromosome 11, which contains
83 candidate genes, including neurofibromin (Nf1; Figure 1f).
We sequenced all exons of Nf1 in DNA extracted
from embryonic day (E) 11.5 Dsk9/Dsk9 embryos and
identified a single nucleotide substitution in exon 33
(ENSMUST00000071325, NCBI m37), which was not present
in the strain of origin (Figure 1g). The nucleotide change
predicts that asparagine 1453 in the C-terminal end of a7c
of the GTPase-activating protein–related domain (GRD) is
replaced with lysine (ENSMUSP00000071289, NCBI m37;
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Figure 1. Dsk9 phenotype and positional cloning. (a) Ears , (b) footpads, and (c) hind feet. (d) Split tail dermis and (e) epidermis. (f) Genetic and physical
map of the Dsk9 interval on chromosome 11. (g) The position and sequence alteration of the Nf1Dsk9 mutation. (h) The GRD of human neurofibromin,
highlighting Asn1451 (analogous to mouse Asn1453) and Lys1444 (ENSP00000351015) (Scheffzek et al., 1998). (i) Predicted protein sequence for Nf1Dsk9
aligned with homologous sequences in other species. (j) Pixel intensity of split dermis and epidermis of adult tails (mean±SEM). Individual dots represent
the value from each skin sample examined. Statistical analysis: þ /þ versus Nf1Dsk9/þ dermis, P¼ 0.000165. Nf1tm1Par/þ versus ACTB-cre/þ ; Nf1tm1Par/þ
dermis, P¼ 0.0139. þ /þ versus Nf1Dsk9/þ epidermis, P¼ 0.0279. Nf1tm1Par/þ versus ACTB-cre/þ ; Nf1tm1Par/þ epidermis, P¼0.0032. Dsk9, Dark skin 9;
GRD, GTPase-activating protein–related domain.
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Figure 1h). The GRD of neurofibromin accelerates the
conversion of active RAS–GTP to inactive RAS–GDP, within
the mitogen-activated protein kinase signaling pathway.
Asn1453 is conserved through Drosophila (Figure 1i), and
mutational analysis screening has shown that it is important
for interactions with RAS (Morcos et al., 1996). Missense
mutations in the human NF1 GRD have been previously
reported in neurofibromatosis type 1 patients (Scheffzek
et al., 1998). The most frequently altered human residue in
the GRD is also located on a7c (Lys1444, Figure 1h;
Scheffzek et al., 1998).
Several other lines of evidence suggest that activation of
the mitogen activated protein kinase pathway can cause
darker skin. In addition to neurofibromatosis type 1, multiple
CALMs are a feature of Legius syndrome, which is caused
by loss-of-function mutations in SPRED1, another negative
regulator of mitogen-activated protein kinase signaling
(Brems et al., 2007). Transgenic mice expressing activated
HA-RAS in melanocytes exhibit both epidermal and dermal
hyperpigmentation, the only darker-skinned mouse trans-
genic known to do so (Powell et al., 1995).
Knockout alleles of Nf1 have been studied by other groups
and have not been reported to have a darker skin pheno-
type. We analyzed a Nf1 knockout allele (Jacks et al., 1994)
(Nf1tm1Tyj) and a Nf1 floxed allele (Zhu et al., 2001)
(Nf1tm1Par) crossed to a ubiquitously expressed Cre line
(Lewandoski et al., 1997) (Tg(ACTB-cre)2Mrt). We group
photographed split tail samples and quantified the darkness of
the dermis and epidermis in terms of mean pixel intensity
(Figure 1j, Supplementary Figure S1 online and Table 1).
We found that both Nf1tm1Par/þ ; ACTB-cre/þ (hereafter
referred to as Nf1ACTB-cre KO/þ ) and Nf1tm1Tyj/þ mice have
darker skin.
The Nf1tm1Tyj allele targets exon 40, whereas the Nf1tm1Par
allele targets exons 40 and 41, all of which are downstream
of the GRD, mutated in Nf1Dsk9. However, neurofibromin
protein was not detected in whole homozygous Nf1tm1Tyj
embryos by western blotting, and thus the Nf1tm1Tyj allele
is likely a complete null (Jacks et al., 1994). The darker
skin phenotype in these targeted Nf1 alleles indicates that
loss-of-function mutations in Nf1 cause skin hyperpigmen-
tation in mice, as they do in humans (De Schepper et al., 2005).
Effects of homozygous loss of neurofibromin on melanocytes
Homozygosity of Nf1tm1Tyj is lethal at E13.5 owing to cardiac
defects (Jacks et al., 1994). Similar to Nf1tm1Tyj, Nf1Dsk9/
Nf1Dsk9 embryos dissected at E12.5 exhibit edema, hemor-
rhage, and small, hypopigmented eyes (Figure 2a and b). To
be able to study the effects of homozygous loss of Nf1 in
melanocytes in adult mice, we used Tg(Mitf-cre)7114Gsb,
which expresses Cre in melanoblasts under the control of the
melanocyte-specific 1 M promoter of Microphthalmia, to
knock out the floxed Nf1tm1Par allele beginning at E11.5
(Alizadeh et al., 2008). The resulting Mitf-cre/þ ; Nf1tm1Par/
Nf1tm1Par animals (hereafter referred to as Nf1Mitf-cre KO/
Nf1Mitf-cre KO) exhibited a very dark glabrous skin dermis and
a darker epidermis (Figure 2c and d, quantified in Supple-
mentary Figure S2 online and Table 1).
In histological sections, adult Nf1Mitf-cre KO/Nf1Mitf-cre KO
animals exhibit an increase in the amount of melanin in the
tail dermis and epidermis compared with wild type animals
(Figure 2e and f). The trunk skin dermis typically bears only a
few pigmented cells in mice (example in Figure 2g); however,
they are frequently observed in Nf1Mitf-cre KO/Nf1Mitf-cre KO
animals (Figure 2h). Over time, patches of darker dermis form
in the neck region of both Nf1Mitf-cre KO/Nf1Mitf-cre KO and
Nf1Mitf-cre KO/Nf1Dsk9 mice, but never in Nf1Mitf-cre KO/þ or
Nf1Dsk9/þ littermates (Supplementary Figure S3 online). The
trunk skin epidermis of Nf1Mitf-cre KO/Nf1Mitf-cre KO mice is
unpigmented, as it is in normal mice (Figure 2g and h).
We next used two melanocyte reporters to study the
melanoblasts in Nf1 homozygous mutant embryos. First,
Table 1. Skin hyperpigmentation in various Nf1 knockouts (KO)
Genotype Cell type(s) targeted
Increase in average pixel
intensity of the dermis
compared with wild-type
littermates
Increase in average pixel
intensity of the epidermis
compared with
wild-type littermates
Nf1Dsk9/+ All 13% (±2%) 9% (±4%)
Nf1tm1Tyj /+ All 24% (±7%) 1
Nf1ACTBcre KO/+ All 22% (±8%) 13% (±3%)
Nf1Mitfcre KO/Nf1Mitfcre KO Committed melanocytes 70% (±8%) 14% (±6%)
Nf1Plp1cre KO/+
(E11.5 tamoxifen injection)
Bipotential Schwann cell-melanoblast
precursors expressing Plp1-creER at E11.5
8% (±3%) None
Nf1Mitfcre KO/+ Committed melanocytes None None
Nf1Mitfcre KO + S100a4cre KO/+ Committed melanocytes, keratinocytes, and
fibroblasts
None None
Nf1Mitfcre KO + Vav1cre KO/+ Committed melanocytes and hematopoietic cells None None
Quantification of the percent increases in the mean pixel intensity of different Nf1 mutant tail dermis and epidermis.
1The epidermis was not examined in these mice. At the time of this experiment, the epidermal hyperpigmentation of Nf1Dsk9 mice had not been identified.
It was missed in the initial survey of the Dsk mice (Fitch et al., 2003).
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Figure 2. Homozygous knockout (KO) of Nf1. (a, b) E12.5 embryos. (c, d) Split tail dermis and epidermis. (e–h) Hematoxylin- and eosin-stained
sections. Melanin in the epidermis (ep, white arrows) and dermis (der, black arrows). Clusters of melanin-containing cells (arrowhead). (i) Percentage of
cells sorted from E15.5 trunk skin (mean±SEM). (j–m) E10.5 Dct-Lacz/þ embryos. Boxed areas are shown in higher magnification. LacZ-positive cells are
observed to the left of the line in m. (n) Immunofluorescence for Dct-LacZ (green) and Tuj1 (red) at E11.5. White arrow indicates a double-positive cell;
yellow arrow points toward the dorsal aspect. Neural tube (nt). Bars: a and b, 500 mM; e–h, 50mM; j and k, 200 mM; n, 30 mM. Statistical analysis: þ /þ
versus Nf1Mitf-cre KO/Nf1Mitf-cre KO in i, P¼0.0238. Dsk9, Dark skin 9; Wt, wild type.
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we crossed the Rosa26-LoxP-Stop-LoxP-EYFP reporter line
(Srinivas et al., 2001) (Gt(ROSA)26Sortm1(EYFP)Cos/J) toMitf-cre
and Nf1tm1Par, and FACS-sorted the EYFP-positive cells in
Nf1Mitf-cre KO/Nf1Mitf-cre KO, Nf1Mitf-cre KO/þ , and þ /þ
embryos. We found a 2.4-fold increase in the percentage
of EYFP-positive cells in the trunk skin of Nf1Mitf-cre KO/
Nf1Mitf-cre KO embryos at E15.5 as compared with wild type
(Figure 2i).
Next, we crossed Nf1Dsk9 to the melanocyte reporter
transgenic line, Dct-LacZ (Tg(Dct-LacZ)A12Jkn) (Mackenzie
et al., 1997). Dct encodes dopachrome tautomerase, a
melanogenic enzyme expressed beginning at E10.5
(Mackenzie et al., 1997). At E10.5, Nf1Dsk9/Nf1Dsk9 embryos
expressing Dct-LacZ showed a marked increase in LacZ-
positive cells in the head and neck region (Figure 2j and k).
We noted that in Nf1Dsk9/Nf1Dsk9 embryos, LacZ-positive
cells were located at a position more dorsal to any in þ /þ
embryos (Figure 2l and m). At E11.5, we found colocalization
of LacZ with a neuronal marker, Tuj1, in migratory cells
situated at the most dorsal positions in Nf1Dsk9/Nf1Dsk9
embryos (Figure 2n and quantified in Supplementary Figure
S4 online). These cells could be melanoblasts, as Tuj1 has
been reported to be expressed in some melanoblasts
(Adameyko et al., 2012), or these cells might be neuronal
progenitors (Jiao et al., 2006). The number of Dct-LacZ-
positive, Tuj1-negative cells was increased 3.2-fold in
Nf1Dsk9/Nf1Dsk9 embryos as compared with wild type at
E11.5 (Supplementary Figure S5 online).
One of the features of neurofibromatosis type 1 is the
presence of multiple CALMs. CALMs are epidermal,
tan-brown, clearly demarcated macules with smooth borders
and an increased melanocyte density, and they usually
develop during early childhood (De Schepper et al., 2006).
Melanocytes within CALMs have a second hit in the NF1
gene (Maertens et al., 2007; De Schepper et al., 2008), and
thus the Nf1Mitf-cre KO/Nf1Mitf-cre KO mice might serve as an
animal model for this lesion. As with CALMs, which are
typically benign, we found no evidence that homozygous loss
of Nf1 in melanocytes is tumorigenic in mice. We conclude
that there is a mechanism by which homozygous loss of
neurofibromin in melanoblasts increases melanocyte num-
bers beginning early during development.
Dermal hyperpigmentation in Nf1 heterozygotes
In contrast to Nf1Dsk9/þ , Nf1ACTB-creKO/þ , and Nf1Mitf-cre KO/
Nf1Mitf-cre KOmice,Nf1Mitf-cre KO/þ mice do not have a darker
dermis (Figure 3a). Consistent with this, Nf1Mitf-cre KO/þ
embryos carrying the Rosa26-LoxP-Stop-LoxP-EYFP reporter
do not exhibit an increase in the percentage of EYFP-positive
cells at E15.5 (Figure 2i). There are several possible
explanations for the observed lack of a pigmentary phenotype
in Nf1Mitf-cre KO heterozygotes. For example, neurofibromin
haploinsufficiency might be required in another cell type
besides melanocytes in order to produce a darker dermis, or
Mitf-cre might not recombine the Nf1tm1Par allele at the
correct stage of development.
We first addressed whether Nf1 haploinsufficiency alters
paracrine signaling initiated by other cells of the dermis,
such as fibroblasts (Shishido et al., 2001) and mast cells
(Yang et al., 2006, 2008), which could affect melanocytes.
To recombine Nf1tmPar1 in the skin, we reproduced a
previously described transgenic line that expresses Cre in
fibroblasts and keratinocytes, under the S100a4 EF-hand
calcium-binding protein promoter (Supplementary Figures S6
and S7 online; (Shrestha et al., 1998; Bhowmick et al., 2004).
We also obtained a transgenic line expressing Cre under the
Vav1 Dbl family guanine nucleotide exchange factor pro-
moter to recombine Nf1tmPar1 in hematopoietic cells, inclu-
ding mast cells of the skin (Tg(Vav1-cre)A2Kio/J) (de Boer
et al., 2003). We did not detect any alteration in dermis
pigmentation in either Nf1tmPar1/þ ; Mitf-cre/þ ; S100a4-cre/
þ (Nf1S100a4-creþMitf-cre KO/þ ) or Nf1tmPar1/þ ; Mitf-cre/þ ;
Vav1-cre/þ (Nf1Vav1-creþMitf-cre KO/þ ) mice (Figure 3a).
We then compared the fraction of cells that are Dct-LacZ-
positive or EYFP-positive in Dct-LacZ/þ or Mitf-cre/þ ;
Rosa26-LoxP-Stop-LoxP-EYFP/þ E15.5 trunk skin, respec-
tively. From this, we estimate that the Mitf-cre transgene
induces recombination at the Rosa26 locus in about a
quarter of melanoblasts by E15.5 (24%±8%, SEM). In adult
Nf1Mitf-cre KO/þ mice, we detected the recombined Nf1
allele by PCR in ear skin DNA samples, where a minority of
melanocytes is mixed with more abundant keratinocytes and
fibroblasts (Supplementary Figure S6 online). As Mitf-cre is
sufficient to induce a phenotype in Nf1Mitf-cre KO/Nf1Mitf-cre KO
embryos, but not in Nf1Mitf-cre KO/þ embryos by E15.5
(Figure 2i), we wondered whether Nf1 haploinsufficiency
might be required before E15.5 to cause darker skin. Perhaps
Mitf-cre is not expressed in a sufficient number of melano-
blasts during some critical early melanoblast stage, or
perhaps knockout must occur within melanoblast precursors.
Thus, we used a tamoxifen-inducible, Plp1 promoter–
driven Cre line (Doerflinger et al., 2003; Adameyko et al.,
2009), Tg(Plp1-cre/ERT)3Pop, which is expressed in bipoten-
tial Schwann cell-melanoblast precursors, to recombine the
Nf1tm1par allele. A single injection of tamoxifen at E11.5 of
development induced a darker tail dermis in Nf1tmPar1/þ ;
Plp1-creER/þ (Nf1Plp1-creER KO/þ ) animals, as compared
with their littermates without Plp1-creER (Figure 3b, Table 1).
Injection of tamoxifen at E9.5 did not darken the dermis
(Figure 3c). Consistent with the timing of these two tamoxifen
injections (E11.5 vs. E9.5), we observed an increased number
of LacZ-positive cells in Nf1Dsk9/þ embryos carrying the
Dct-LacZ reporter at E12.5, but not at E10.5 (Figure 3d). At
E12.5, we quantified the number of LacZ-positive cells in the
skin overlying the dorsal root ganglia in the trunk and found a
significant increase in Nf1Dsk9/þ embryos (Figure 3e). This is
a site where melanoblasts are known to differentiate from
Schwann cell precursors at E11.5 (Adameyko et al., 2009).
These experiments indicate that neurofibromin haplo-
insufficiency acts during a narrow window of time during
development to cause darker skin.
Epidermal hyperpigmentation in Nf1 heterozygotes
Unlike the dermis, which is fairly uniform in pigmentation,
the epidermis of the mouse tail is pigmented in a highly
organized pattern (Figure 4a). Rows of scales, each associated
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with a few hairs, ring the tail from base to tip (Schweizer and
Marks, 1977). Only an oval in the center of each scale is
pigmented, where melanocytes are concentrated. The dor-
sum of the tail is darker than the ventrum.
The darker epidermis in Nf1Dsk9/þ mice can be appre-
ciated by examining the whole epidermis split from the
dermis (Figure 1e), as well as by comparing individual scales
at a specific dorsal–ventral position under magnification
(Figure 4a and b). To determine whether melanocyte
numbers are increased in Nf1Dsk9/þ epidermis, we removed
the tail skin of adult Nf1Dsk9/þ and þ /þ animals carrying
Dct-LacZ, stained it with X-gal (5-bromo-4-chloro-3-indolyl-
b-D-galactoside), and then split the dermis and epidermis
(Figure 4c and d). We observed a general relationship
between the density of LacZ-positive cells and the darkness
of the scales (Figure 4e) and found that Nf1Dsk9/þ animals
exhibit a 24% (±8%) increase in LacZ-positive cells per
mm2. We conclude that the increase in pigmentation in the
Nf1Dsk9/þ epidermis is caused, at least in part, by an
increased number of melanocytes.
Similar to the dermis, the epidermis of Nf1Mitf-cre KO/þ
and Nf1S100a4-cre KO/þ mice is not darker (Figure 4f). We
examined the tails of Nf1P1p1-creERKO/þ animals produced by
injecting 1mg tamoxifen at E11.5 and found that, despite the
darker dermis (Figure 3b), the epidermis is unaffected (Figure
4f). To examine this intriguing finding further, we used
Rosa26-LoxP-Stop-LoxP-LacZ reporter mice (Soriano, 1999)
(Gt(Rosa)26Sortm1Sor/J) to fate map melanocytes express-
ing Plp1-creER at E11.5. Previously, Adameyko et al.
(2009) reported that the same injection of tamoxifen induced
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Figure 3. Effects of heterozygous knockout (KO) of Nf1 in various cell types. (a–c) Pixel intensity of dermis from adult tails (mean±SEM) using different
Cre lines: (a, left) Mitf-cre alone, (a, middle) Mitf-cre plus S100a4-cre, (a, right) Mitf-cre plus Vav1-cre, and (b) Plp1-cre with an injection of tamoxifen
at either E11.5 or (c) E9.5. (d) Dct-LacZ/þ embryos dissected at E10.5 (upper panel) or E12.5 (middle and lower panels). (e) Number of Dct-LacZ-positive
cells per mm2 in the skin overlying the 4th through 6th dorsal root ganglia of the trunk at E12.5, labeled in the lowest panel of d (mean±SEM). Bars: d, 100 mM.
Statistical analysis: wild type (Wt) versus Nf1Plp1-creER KO/þ in b, P¼ 0.0218. þ /þ versus Nf1Dsk9/þ in e, P¼0.0052. Dsk9, Dark skin 9.
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Plp1-creER-mediated recombination of Rosa26-LoxP-Stop-
LoxP-EYFP in 66% of P11 trunk hair follicle melano-
cytes (Adameyko et al., 2009). We analyzed the tail skin
and found many LacZ-positive cells in the hair follicles
(Figure 4h), but almost none in the interfollicular epidermis
(Figure 4k). We conclude that it was not possible for the tail
epidermis to be darker in the Nf1Plp1-creER KO/þ mice, as
the interfollicular epidermis mostly lacks melanocytes that
express Plp1-creER at E11.5. This experiment shows that
distinct groups of melanocytes populate the dermis/hair
follicles and the interfollicular epidermis, a previously
unappreciated complexity of melanoblast development. We
speculate that an as yet unmapped lineage of melanoblasts
requires Nf1 haploinsufficiency before cell fate commitment
to generate a darker tail epidermis. As migrating melanoblasts
seem to be attracted to hair follicles (Jordan and Jackson,
2000; Peters et al., 2002), it could be that the first wave
of epidermal melanoblasts mostly end up in hair follicles,
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Figure 4. Epidermal pigmentation in Nf1 heterozygous mice. (a–d) Epidermal scales with (c, d) and without (a, b) X-gal staining, from the center
dorsum of adult tails. (e) Scatter plot of scale pixel intensity versus the number of LacZ-positive cells per mm2 of scale. (f) Pixel intensity of the epidermis
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leaving later waves of melanoblasts to populate the inter-
follicular epidermis.
DISCUSSION
We have found that mutations in neurofibromin (Nf1) cause
dark skin in mice, as they do in humans. Among the genes
known to cause skin hyperpigmentation in mice, Nf1 is
unique in that it darkens both the dermis and the epidermis
(Fitch et al., 2003). As homozygous loss of Nf1 is lethal, we
decided to make a homozygous knockout of Nf1 specifically
in melanocytes to study the effects on pigmentation in adults.
To our surprise, the heterozygous knockout mice produced as
a by-product of this cross had no skin darkening. Thus, our
focus turned to determining which cell type is affected by
Nf1 haploinsufficiency, with the interesting conclusion that
heterozygous and homozygous Nf1 knockout apparently act
by different mechanisms. Further experiments revealed
that heterozygous knockout of Nf1 in bipotential Schwann
cell-melanoblast precursors produces darker skin.
Essential to our analysis is the comparison of the knockout
in melanocytes (by Mitf-cre) with the knockout in Schwann
cell precursors (by Plp1-creER). Mitf is a master regulator of
melanocyte development, and it is upregulated immediately
following the differentiation of melanoblasts from Schwann
cell precursors, with a concurrent downregulation of Plp1
(Widlund and Fisher, 2003; Adameyko et al., 2009).Mitf-cre,
which should be expressed in all melanoblasts, only induced
recombination in 24% by E15.5, and thus it is possible that
the Nf1Mitf-cre KO/þ animals had no phenotype because not
enough melanoblasts underwent recombination. How-
ever, we found no increase in melanoblast number in
Nf1Mitf-cre KO/þ embryos at E15.5, which could have been
observed even if the increase was too small to cause a visible
change in adult skin color. In addition, it seems unlikely that
there is an ongoing increase in proliferation/survival in Nf1
haploinsufficient melanocytes, as this would eventually have
caused darker skin in the Nf1Mitf-cre KO/þ adults. Thus, if
Nf1 haploinsufficiency in already committed melanoblasts
has an effect, we think that it is for a limited amount of time
early during development.
Plp1-creER expresses a fusion protein of Cre recombinase
with the estrogen receptor. To reside in the nucleus, CreER
must be bound to tamoxifen. Because tamoxifen interferes
with pregnancy, we could only inject it on a single day.
We chose E11.5, which had been previously shown to be a
useful time point in which to target Plp1-expressing cells in
the trunk (Adameyko et al., 2009). However, the efficiency in
Schwann cell precursors surrounding the dorsal root ganglia
is only 61%. In addition, melanoblasts born from Schwann
cell precursors before E11.5 do not undergo recombination
(Adameyko et al., 2012). This may explain why the dermis
exhibited an 8% increase in darkening in Nf1Plp1-creER KO/þ
animals, compared with a 22% increase in Nf1ACTB-cre KO/þ
animals (Table 1).
From these findings, we suggest two possible roles for Nf1
gene dosage in pigmentation: (1) Nf1 haploinsufficiency
increases the production of melanoblasts from Schwann cell
precursors, but does not alter melanoblast survival/prolifera-
tion, or (2) Nf1 haploinsufficiency increases melanoblast
survival/proliferation, but only for a short period of time.
We favor the first possibility, because our studies of the
Nf1Dsk9/þ phenotype show that the effects of Nf1 haploin-
sufficiency are visible immediately after melanoblasts differ-
entiate from Schwann cell precursors along the dorsal root
ganglia (with a 1.7-fold increase in cell number by E12.5;
Figure 5).
The interconnectedness of melanocytes and Schwann
cells is apparent in the features of neurofibromatosis type 1.
In addition to generalized epidermal hyperpigmentation and
CALMs, skin hyperpigmentation can specifically overlie
Nf1 +/–
Mitf+
Dct+
SCPs
NCCs
Plp1+
DRG
SOM
NT Epidermis
Dermis
Nf1 –/–
Mbs
MCs
E11.5
Figure 5. Requirement for Nf1 during melanocyte development. Homozygous Nf1 loss in committed melanoblasts (Mbs) darkened the skin. Haploinsufficiency
of neurofibromin in committed melanoblasts via Mitf-cre did not alter skin pigmentation; however, haploinsufficiency in E11.5 Schwann cell-melanoblast
precursors (SCPs) via Plp1-creER darkened the dermis. SCPs that express Plp1 at E11.5 (red fate mapped cells) contribute to melanocytes (MCs) in the dermis and
hair follicles, but not the interfollicular epidermis. DRG, dorsal root ganglia; NCCs, neural crest cells; NT, neural tube; SOM, somite.
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superficial plexiform neurofibromas, resembling giant con-
genital melanocytic nevi (Boyd et al., 2009). Some-
times neurofibromas are laden with melanin-containing
cells (Fetsch et al., 2000). Similar phenotypes are seen
in mice. Wu et al. (2008) knocked out both copies of
Nf1 in Schwann cell precursors using a Desert hedgehog-
cre-expressing transgene, and found that 39% of the mice
exhibited hyperpigmentation overlying the plexiform
neurofibromas/spinal cord. This was not reported for neuro-
fibromas in Plp1-creER homozygous knockout mice, when
tamoxifen was administered either perinatally or in adult-
hood, suggesting that perhaps Plp1-creER-expressing cells in
adults do not produce melanocytes (Mayes et al., 2011).
Recently described skin-derived precursors are neural
crest–like stem cells present in the postnatal dermis that can
differentiate along neuronal and glial lineages, and thus may
serve as a reservoir for melanocytes in adult skin (Zabier-
owski et al., 2011). Nf1-null skin-derived precursors develop
into dermal neurofibromas when implanted in adult mice
(Le et al., 2009). It is possible that skin-derived precursors or
dermal stem cells are playing a role in maintaining the
generalized skin hyperpigmentation and/or CALMs of neuro-
fibromatosis throughout adulthood. Study of tail pigmentation
in mice implanted with Nf1 null skin-derived precursors
could address this.
Neurofibromatosis is one of the most common genetic
diseases, affecting B1:3,500 individuals. Although the
pigmentary alterations of neurofibromatosis are tolerable,
the developmental connection between melanocytes and
Schwann cells requires that we understand the role of
neurofibromin in both. We find that neurofibromin protein
levels have an early role in the glial lineage of melanoblasts,
different from the effects of complete neurofibromin loss.
Future steps will be to determine whether immature Schwann
cell numbers are altered in Nf1 heterozygous embryos, to
determine whether homozygous Nf1 loss in adulthood can
cause hyperpigmentation, and to pinpoint the developmental
origin of interfollicular melanocytes.
MATERIALS AND METHODS
See the Supplementary data online section for more detailed
information.
Mice
Nf1Dsk9, S100A4-cre, Dct-LacZ, and Mitf-cre mice were maintained
on a C3HeB/FeJ background. Plp1-creER, Nf1tm1Tyj, Tg(Vav1-cre)
A2Kio/J, Gt(ROSA)26Sortm1(EYFP)Cos/J, Gt(Rosa)26Sortm1Sor/J, and
Nf1tm1Par mice were obtained on an inbred C57BL6/J background.
For embryo collection and tamoxifen injection, the noon of the
day the copulatory plug was found was marked as day 0.5 of
gestation. Dsk9 was mapped as previously described (Fitch et al.,
2003). S100a4-cre mice were made by subcloning 3.44 kb
of the S100a4 promoter from a positively identified C57BL/6 BAC
clone (RP23: 284L9) into pSP72 upstream of Cre. Purified targeting
vector was digested by NotI and SphI and microinjected into
hybrid (129; C57 F1) pronuclear stage embryos to generate two
founder lines. Experiments were performed under the approval of the
CACC at University of British Columbia.
Whole-mount staining
Embryos, trunk skin, and tail skin samples were incubated with
X-gal staining solution as previously described (Van Raamsdonk
et al., 2004). The tail dermis and epidermis were split using sodium
bromide.
Tamoxifen
Tamoxifen was dissolved in a sunflower oil/ethanol (10:1) mixture at
a concentration of 10mgml1. Pregnant females were injected
intraperitoneally with 1mg.
Immunofluorescence
Frozen embryo sections (8 mM) were blocked in 4% donkey
serum and incubated with 1:1,000 anti-Tuj1 antibody (Covance,
Princeton, NJ) and 1:500 anti-b-galactosidase antibody (Promega,
Madison, WI). The following day, the sections were incubated with
Alexa594-conjugated anti-rabbit antibody and Alexa488-conjugated
anti-mouse antibody (Invitrogen, Grand Island, NY).
FACS analysis
The trunk skin of E11.5 embryos was removed and dissociated in
trypsin for 15minutes. Cells were sorted for EYFP expression and
counted using a FACS LSRII cell sorter (Franklin Lakes, NJ).
Statistics
Jump was used to determine whether all data were distributed
normally using the Shapiro–Wilk W test. Individual data points
were plotted to indicate the range, given that some of the
crosses were made on a mixed background of C3H and C57.
P-values of statistical significance were calculated using either
Student’s t-test or analysis of variance and are indicated in the
figure legends.
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